CEO and CFO of Rare Disease Treatment Company Sell Shares Worth Billions After Stock Options 'Jackpot'

According to a U.S. Securities and Exchange Commission filing, United Therapeutics Corporation’s (NASDAQ: UTHR) Chief Financial Officer and its Chairman and CEO consecutively exercised stock options between April 20 and 22 and sold a portion of the resulting shares in the open market. CFO James Edgemon exercised 10,000 options at a strike price of $135.42 per share, acquired the same number of shares, and then sold them all at roughly $572 to $585 each, generating proceeds of approximately $58–$59 million (around ₩8 billion). Following that sale, his direct holdings declined to about 18,876 shares.

Chairman and CEO Martin Rosblatt exercised a total of 19,000 options with a $146.03 strike price on April 21 and 22, selling 16,000 shares at about $564 to $580 apiece. That transaction yielded close to $90 million (around ₩10 billion) in cash. The company notes that these trades were executed under a pre-established Rule 10b5-1 trading plan, and Rosblatt still retains 40,513 shares directly, along with a substantial indirect stake through family trusts.

In its May 6 release, United Therapeutics reported first-quarter 2026 results of $781.5 million in revenue, $274.9 million in net income, and $5.82 in diluted earnings per share. During the quarter, the company announced positive data from key clinical trials—ADVANCE OUTCOMES for pulmonary arterial hypertension and TETON-1 for pulmonary fibrosis—and received FDA approval to begin its UHeart xenogeneic organ transplant trial implanting porcine hearts into humans.

Headquartered in Silver Spring, Maryland, and Research Triangle Park, North Carolina, United Therapeutics is a biotech firm that develops and markets treatments for severe and rare diseases such as pulmonary arterial hypertension, orphan lung disorders, and pediatric cancers. Founder and CEO Martin Rosblatt has driven the company’s growth through its pulmonary hypertension portfolio, including Tyvaso and Remodulin. United Therapeutics is currently classified as a mid-cap biotech company listed on the Nasdaq.